More Than One-Half Of Patients With Crohn's Disease Treated With Lilly's mirikizumab Achieved Clinical Remission At One Year, Including Patients With Previous Biologic Failure
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly's drug mirikizumab has shown promising results in treating Crohn's disease, with over half of the patients achieving clinical remission after one year, including those who had previously failed other biologic treatments.
May 21, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's mirikizumab has demonstrated significant efficacy in treating Crohn's disease, with over half of the patients achieving clinical remission after one year, including those with previous biologic treatment failures.
The positive clinical trial results for mirikizumab in treating Crohn's disease, especially in patients who had failed previous biologic treatments, are likely to boost investor confidence in Eli Lilly's product pipeline and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100